Therapy
Biotechnology
Health

Intellia Therapeutics

$17.41
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.51 (3.02%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell NTLA and other stocks, options, ETFs, and crypto commission-free!

About NTLA

Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. Read More The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Employees
211
Headquarters
Cambridge, Massachusetts
Founded
2014
Market Cap
845.13M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
494.90K
High Today
$17.54
Low Today
$16.95
Open Price
$17.09
Volume
824.80K
52 Week High
$32.95
52 Week Low
$11.03

Collections

Therapy
Biotechnology
Health
Medical
Technology
2016 IPO
US
North America

NTLA News

ReutersAug 6

Edited Transcript of NTLA earnings conference call or presentation 1-Aug-19 12:00pm GMT

43

NTLA Earnings

-$0.61
-$0.55
-$0.49
-$0.43
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
Actual
Expected Oct 30, Pre-Market

Popular Stocks

More NTLA News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.